Successful use of pooled sera to estimate HIV antibody seroprevalence and eliminate all positive cases. NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Successful use of pooled sera to estimate HIV antibody seroprevalence and eliminate all positive cases.

Asia Pac J Public Health. 1992-93;6(3):146-9. Unique Identifier : AIDSLINE MED/94114308
Ko YC; Lan SJ; Chiang TA; Yen YY; Hsieh CC; School of Public Health and Graduate Institute of Medicine,; Kaohsiung Medical College, Taiwan, ROC.

Abstract: Pooling specimens when testing them in large numbers can save scarce resources and several earlier reports have indicated this to be a feasible strategy. In an HIV antibody mass screening test carried out in our laboratory, we used Dorfman's two-stage model. We sought to establish the optimal number of specimens in a pool, and to achieve maximum efficiency while maintaining both sensitivity and specificity. Before testing for HIV antibody, five positive samples were placed in a set of 1012 sera in a double blind manner, one positive sample into a second set of 1012 sera and none in a third set. The positive rate was assumed to be 0.2% for each set of 1012 sera. As indicated by our model, 22 individual serum samples were placed into each of 46 pools which, when tested by particle agglutination assays, lead to the identification of all positive samples. We concluded that the prevalence rate can be estimated in the first stage, 95% confidence intervals were given, and the efficiency rate could be calculated for the identification of all infected specimens in a large number of samples showing low prevalence rates.
Keywords: Blood Specimen Collection/METHODS Comparative Study Double-Blind Method False Positive Reactions Human *HIV Seroprevalence Mass Screening/*METHODS *Models, Theoretical Sensitivity and Specificity Support, U.S. Gov't, P.H.S. CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIALKWDbloodspecimencollection/methodscomparativestudydouble-blindmethodfalsepositivereactionshumanKWDhivseroprevalencemassscreening/KWDmethodsKWDmodels,theoreticalsensitivityandspecificitysupport,uKWDsKWDgov't,pKWDhKWDsKWDclinicaltrialjournalarticlerandomizedcontrolledtrial
940430
M9440866

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .